EU attempts to tackle parallel pricing of drugsBMJ 1998; 316 doi: https://doi.org/10.1136/bmj.316.7147.1769a (Published 13 June 1998) Cite this as: BMJ 1998;316:1769
- Rory Watson
The European Union is conducting a major investigation into the different prices charged for the same medicines in its 15 member states. Pressure for the exercise has come from EU governments after complaints from the pharmaceutical industry that a parallel trade has grown that undercuts the price of many domestic products.
Drug prices are set by governments. The rate is determined by what a national health service can afford and by the importance of the pharmaceutical industry in a particular country. If the price for a particular drug is considerably lower in one member state, however, an enterprising trader will buy it there and export …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial